OrbiMed’s Alto Neuroscience ANRO Stock Holding History

OrbiMed’s Portfolio ANRO Stock Details ANRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$3.77M	Buy	167,500 +42,500	+34%	+$788K	0.07%	98
2025 Q4	$2.23M	Sell	125,000 -125,000	-50%	-$1.57M	0.05%	98
2025 Q3	$1M	Hold	250,000	–	–	0.02%	103
2025 Q2	$550K	Hold	250,000	–	–	0.01%	96
2025 Q1	$540K	Hold	250,000	–	–	0.01%	107
2024 Q4	$1.06M	Buy	+250,000	New	+$1.56M	0.02%	111

Other funds holding ANRO

AWG

Alpha Wave Global New York $791M AUM 113.77% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

SSC

Spruce Street Capital New York $416M AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

OrbiMed's ANRO Position: Q1 2026 in Review

OrbiMed increased its Alto Neuroscience (ANRO) stake by 34% in Q1 2026, buying an estimated $788K and bringing the position to 167,500 shares worth $3.77M. The position accounts for 0.07% of the portfolio, ranked #98.

OrbiMed first reported a position in ANRO in Q4 2024 and has held it in 6 quarters since. 110 funds tracked by Wall St. Rank hold ANRO as of Q1 2026.

OrbiMed held 167,500 shares of Alto Neuroscience worth $3.77M as of Q1 2026.
OrbiMed bought 42,500 Alto Neuroscience shares in Q1 2026, an estimated $788K.
Alto Neuroscience made up 0.07% of OrbiMed's portfolio in Q1 2026, its #98 holding.
OrbiMed first reported a position in Alto Neuroscience in Q4 2024 and has held it in 6 quarters since.
110 funds tracked by Wall St. Rank held Alto Neuroscience as of Q1 2026.

Based on OrbiMed's 13F filing for Q1 2026, filed 15 May 2026.